Evidence map›Paper›PMID 28065789›Full record

ArticleGastroenterology2017

Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.

Xi-Meng Lin, Liang Hu, Jin Gu, Ruo-Yu Wang, Liang Li, Jing Tang, Bao-Hua Zhang, Xing-Zhou Yan, Yan-Jing Zhu, Cong-Li Hu and 7 more

Abstract read
In one paragraph

Article in Gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. A CHKA-PML autophagy checkpoint enables tumors to evade glutamine starvation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. The role of phosphatidylcholine metabolism in tumors.Medical oncology (Northwood, London, England) · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Xi-Meng LinInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China; Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Liang HuInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China; Anal-Colorectal Surgery Institute, 150th Hospital of PLA, Luoyang, China.
Jin GuTsinghua National Laboratory for Information Science and Technology, Bioinformatics Division, Synthetic and Systems Biology Center, Department of Automation, Tsinghua University, Beijing, China.
Ruo-Yu WangDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Liang LiInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China; National Center for Liver Cancer, Shanghai, China.
Jing TangDepartment of Neurosurgery, Wuhan General Hospital of Guangzhou Command, Wuhan, China.
Bao-Hua ZhangDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Xing-Zhou YanDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Yan-Jing ZhuInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China; National Center for Liver Cancer, Shanghai, China.
Cong-Li HuInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China.
Wei-Ping ZhouDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Shao LiMOE Key Laboratory of Bioinformatics and Bioinformatics Division, Tsinghua National Laboratory for Information Science and Technology, Department of Automation, Tsinghua University, Beijing, China.
Jing-Feng LiuMengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, China.
Frank J GonzalezLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Meng-Chao WuDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Hong-Yang WangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China; National Center for Liver Cancer, Shanghai, China. Electronic address: hywangk@vip.sina.com.
Lei ChenInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China; National Center for Liver Cancer, Shanghai, China; Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, China; Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: chenlei@smmu.edu.cn.
Eastern Hepatobiliary Surgery Hospital · CNSecond Military Medical University · CNTsinghua University · CNCenter for Cancer Research · USMengchao Hepatobiliary Hospital · CNShanghai Cancer Institute · CNWuhan General Hospital of Guangzhou · CN

Funding

Xenobiotic receptorsZIABC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$26.9M
Xenobiotic ReceptorsZIABC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$16.4M
Intramural NIH HHS ZIA BC005562Intramural NIH HHS ZIA BC005708
6 · The paper itself

Abstract

BACKGROUND &

aimsCholine kinase α (CHKA) catalyzes conversion of choline to phosphocholine and can contribute to carcinogenesis. Little is known about the role of CHKA in the pathogenesis of hepatocellular carcinoma (HCC).

methodsWe performed whole-exome and transcriptome sequence analyses of 9 paired HCC and non-tumor-adjacent tissues. We performed tissue chip analyses of 120 primary HCC and non-tumor-adjacent tissues from patients who received surgery in Shanghai, China from January 2006 through December 2009; 48 sets of specimens (HCC and non-tumor-adjacent tissues) were also analyzed. CHKA gene copy number was quantified and findings were validated by quantitative reverse transcription polymerase chain reaction analysis. CHKA messenger RNA and protein levels were determined by polymerase chain reaction, immunohistochemical, and immunoblot analyses. CHKA was examined in 2 hepatocyte cell lines and 7 HCC-derived cell lines, and knocked down with small interfering RNAs in 3 HCC cell lines. Cells were analyzed in proliferation, wound healing, migration, and invasion assays. Cells were injected into tail veins of mice and tumor growth and metastasis were quantified. Immunoprecipitation and immunofluorescence assays were conducted to determine interactions between CHKA and the epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin complex 2.

resultsLevels of CHKA messenger RNA were frequently increased in HCC tissues compared with nontumor tissues; increased expression was associated with amplification at the CHKA loci. Tumors that expressed high levels of CHKA had more aggressive phenotypes, and patients with these tumors had shorter survival times after surgery compared to patients whose tumors expressed low levels of CHKA. HCC cell lines that stably overexpressed CHKA had higher levels of migration and invasion than control HCC cells, and formed larger xenograft tumors with more metastases in mice compared to HCC cells that did not overexpress CHKA. CHKA was required for physical interaction between EGFR and mechanistic target of rapamycin complex 2. This complex was required for HCC cells to form metastatic xenograft tumors in mice and to become resistant to EGFR inhibitors.

conclusionsWe found levels of CHKA to be increased in human HCCs compared to nontumor tissues, and increased expression to be associated with tumor aggressiveness and reduced survival times of patients. Overexpression of CHKA in HCC cell lines increased their invasiveness, resistance to EGFR inhibitors, and ability to form metastatic tumors in mice by promoting interaction of EGFR with mechanistic target of rapamycin complex 2.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, HepatocellularCell LineCell Line, TumorCell MovementCholine KinaseDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideGefitinibHep G2 CellsHumansImmunoblottingImmunohistochemistryLiver NeoplasmsAntineoplastic AgentsCHKA protein, humanCholine KinaseErbB ReceptorsErlotinib HydrochlorideGefitinibMechanistic Target of Rapamycin Complex 2Multiprotein ComplexesQuinazolinesRNA, MessengerTOR Serine-Threonine KinasesLiver CancerOncogeneSignal TransductionTumorigenesis

Identifiers

PMID28065789
PMCPMC6661112
OpenAlexW2567841939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.